rifampicin
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
9886
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
December 05, 2025
Dose modifications of mezigdomide when coadministered with CYP3A4 inhibitors for patients with relapsed/refractory multiple myeloma
(ASH 2025)
- P1/2 | "Introduction: Mezigdomide (MEZI), an oral CELMoD™ agent with potent antimyeloma and immunostimulatory effects, has demonstrated encouraging efficacy in relapsed/refractory multiple myeloma (RRMM) as monotherapy and in combination with dexamethasone/standard treatments (CC-92480-MM-001 [NCT03374085]; CC-92480-MM-002 [NCT03989414])...A phase 1 clinical drug–drug interaction (DDI) study in healthy participants evaluated MEZI as a substrate of cytochrome P450 3A4 (CYP3A4), using rifampin (strong inducer) and itraconazole (strong inhibitor)...Specifically, MEZI CL was reduced 0.15-, 0.11- and 0.38-fold when administered with posaconazole, voriconazole, and fluconazole, respectively... MEZI is a sensitive CYP3A4 substrate. Modeling and simulation provide a robust framework to guide dose adjustments and manage potential DDI risks while preserving efficacy. For pts requiring concomitant use of strong or moderate CYP3A4is, MEZI can be continued safely with dose..."
Clinical • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Neutropenia • Thrombocytopenia
December 12, 2025
P121 Treatment with semaglutide improves the systemic inflammatory burden associated with hidradenitis suppurativa.
(PubMed, Br J Dermatol)
- "The majority of patients (n = 54) had Hurley stage II disease, with 10 patients classified as Hurley stage III and 5 as Hurley stage I. Twenty-two patients were established on adalimumab with two on infliximab. Other biologics prescribed alongside semaglutide included brodalumab (n = 8) and secukinumab (n = 1). Nineteen patients were coprescribed metformin, and for 16 patients rescue antibiotics including rifampicin and clindamycin...Semaglutide can improve not only metabolic control, weight, flare frequency and quality of life, but also systemic inflammation and thus health outcomes (Lyons et al.). Although our findings did not reach statistical significance, the consistent trends observed in inflammatory markers and the established efficacy of semaglutide in weight loss and metabolic improvement suggest that it can enhance health outcomes for this patient population."
Journal • Retrospective data • Dermatology • Genetic Disorders • Hidradenitis Suppurativa • Immunology • Inflammation • Metabolic Disorders • Obesity • Systemic Inflammatory Response Syndrome
December 12, 2025
GD04 (P064) A study of multidrug resistance pattern in scabies-associated infections in endemic communities.
(PubMed, Br J Dermatol)
- "High resistance was noted for erythromycin (91.6%) and ciprofloxacin (53.7%). Gentamicin and clindamycin had moderate susceptibility rates of 57.4% and 51.9%, respectively. Nitrofurantoin and rifampicin maintained high susceptibility (98.1% and 92.6%). Among bacterial strains, methicillin-resistant S. aureus (MRSA) was most prevalent (46.3%), followed by coagulase-negative staphylococci (5.6%) and vancomycin-resistant S. aureus (5.6%)...The high prevalence of MRSA highlights the urgent need for improved infection control measures and the judicious use of antibiotics. While newer drugs like tigecycline, linezolid and daptomycin offer alternative treatment options, robust surveillance and targeted antibiotic stewardship programmes are crucial to address this growing challenge and ensure effective patient care.TableBacteria isolated from 55 patients with scabiesOrganism isolatedn (%)Staphylococcus aureus47 (97)Staphylococcus haemolyticus2 (4)Staphylococcus epidermidis2..."
Journal • Infectious Disease
December 12, 2025
P119 Serum complement, B cells and T cells as markers of treatment response in those treated with adalimumab and clindamycin-rifampicin for hidradenitis suppurativa: a pilot study.
(PubMed, Br J Dermatol)
- "Our patient numbers are small. If these findings are validated in a larger cohort this would begin to allow, for the first time, the personalization of treatment for HS."
Biomarker • Journal • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • CRP
December 12, 2025
P027 A case of cutaneous nodules in a migrant man.
(PubMed, Br J Dermatol)
- "The infectious disease team treated him for multibacillary leprosy with dapsone, rifampicin, clofazimine and steroids. Leprosy is a neglected tropical disease that is under-recognized in Europe, resulting in treatment delay. This is a unique case of leprosy in Ireland, which demonstrates the utility of cutaneous findings and skin biopsy in attaining a diagnosis."
Journal • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Sarcoidosis • CRP
December 12, 2025
CPC02 Follicular eruption unravelling a systemic disease: a clinicopathological correlation.
(PubMed, Br J Dermatol)
- "The patient was subsequently started on weight-based antitubercular therapy (ATT) comprising isoniazid (225 mg), rifampicin (450 mg), pyrazinamide (1200 mg) and ethambutol (825 mg)...Lichen scrofulosorum is a rare tuberculid that occurs in children and young adults. As it can occur in both pulmonary and extrapulmonary forms of TB, a thorough history, cutaneous and systemic examination, and histopathology, microbiology and imaging are essential for prompt diagnosis and early initiation of ATT."
Journal • Cough • Dermatology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis
December 12, 2025
P064 A study of multidrug resistance pattern in scabies-associated infections in endemic communities.
(PubMed, Br J Dermatol)
- "High resistance was noted for erythromycin (91.6%) and ciprofloxacin (53.7%). Gentamicin and clindamycin had moderate susceptibility rates of 57.4% and 51.9%, respectively. Nitrofurantoin and rifampicin maintained high susceptibility (98.1% and 92.6%). Among bacterial strains, methicillin-resistant S. aureus (MRSA) was most prevalent (46.3%), followed by coagulase-negative staphylococci (5.6%) and vancomycin-resistant S. aureus (5.6%)...The high prevalence of MRSA highlights the urgent need for improved infection control measures and the judicious use of antibiotics. While newer drugs like tigecycline, linezolid and daptomycin offer alternative treatment options, robust surveillance and targeted antibiotic stewardship programmes are crucial to address this growing challenge and ensure effective patient care.TableBacteria isolated from 55 patients with scabiesOrganism isolatedn (%)Staphylococcus aureus47 (97)Staphylococcus haemolyticus2 (4)Staphylococcus epidermidis2..."
Journal • Infectious Disease
December 12, 2025
P030 From nerve to nodules: the unexpected progression of pure neuritic leprosy to lepromatous leprosy with erythema nodosum leprosum.
(PubMed, Br J Dermatol)
- "The patient was started on World Health Organization-recommended multidrug therapy with rifampicin, dapsone and clofazimine for 12 months...The patient was started on a regimen of monthly pulsed rifampicin, minocycline and moxifloxacin for 12 months. Thalidomide was started to manage the severe ENL reaction...Only one such case has been previously reported. This emphasizes the need for early diagnosis, vigilant follow-up and awareness of potential disease transformations, particularly in endemic areas."
Journal • Dermatology • Immune Modulation • Immunology • Infectious Disease • Muscular Atrophy • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain
December 12, 2025
Symptom-Based Active Tuberculosis Screening in Two Nigerian Correctional Facilities: A Cross-Sectional Study.
(PubMed, Infez Med)
- "All detected TB cases were rifampicin-sensitive, and no drug-resistant strains was found in this cohort...Policymakers should institutionalize routine ACF in correctional facilities through universal entry screening for all new admissions and at least annual facility-wide screening, with symptom checklists plus rapid molecular testi. Where feasible, this should be combined with portable digital CXR/CAD triage alongside improvement in living conditions and post-release linkage to DOTS."
Journal • Observational data • Cough • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis
December 12, 2025
P012 Metastatic Staphylococcus aureus bacteraemia in atopic dermatitis: a case series.
(PubMed, Br J Dermatol)
- "IV, intravenousPatientClinical manifestationsComplications of SABTreatment of metastatic SABOutcome1Diaphoresis, rigors, nausea, fatigueMitral/aortic valve IE8 weeks IV flucloxacillinRecommenced on methotrexate; good control of AD2ErythrodermaMitral valve IE6 weeks IV flucloxacillinCommenced on dupilumab; excellent control of AD3Pyrexia and rigors following abscess development at footMitral/aortic valve IE6 weeks IV cefazolinMitral valve repair for mitral regurgitation. Recent commencement of dupilumab; AD improving4Erythroderma, subjective fevers, fatigueMRSA bacteraemia with mitral valve IETotal duration 6 weeks 6 days: IV vancomycin → IV daptomycin → IV ceftaroline + vancomycin → oral linezolidRecent recommencement of tralokinumab; AD improving5Right shoulder painSeptic arthritis of right shoulderIV flucloxacillin + vancomycin → 8 weeks daptomycin + rifampicin → 6 weeks doxycyclineCommenced on dupilumab; excellent control of ADAD, atopic dermatitis; IE, infective..."
Journal • Atopic Dermatitis • Cardiovascular • Cognitive Disorders • Dermatitis • Dermatology • Dermatopathology • Immunology • Infectious Disease • Inflammation • Musculoskeletal Pain • Pain • Rheumatology
December 12, 2025
Effects of antibiotic treatments on symbiotic bacteria and life history traits of Bemisia tabaci and Trialeurodes vaporariorum (Hemiptera: Aleyrodidae): implications for pest control strategies.
(PubMed, J Econ Entomol)
- "The antibiotic treatments-tetracycline, rifampicin, and a cocktail of ampicillin, cefotaxime, and gentamicin-significantly altered the abundance of specific symbionts, with notable reductions of Rickettsia in B. tabaci and Arsenophonus in T. vaporariorum. A negative r value was also recorded in B. tabaci following tetracycline treatment. These results highlight the critical role of symbiotic bacteria in whitefly biology and provide insight into the potential consequences of disrupting these associations."
Journal
December 11, 2025
A qualitative study of home- versus facility-based TB treatment for adolescents in Lima, Peru.
(PubMed, Public Health Action)
- "Home-based TB treatment benefits adolescents and caregivers but must be further modified to achieve feasibility and acceptability among HCWs."
Journal • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis
December 11, 2025
Wolfberry prevented liver damage caused by anti-tuberculosis drugs associated with the YAP1/FXR pathway through gut microbiota.
(PubMed, Front Microbiol)
- "Research indicates that first-line anti-tuberculosis drugs (ATDs), including rifampicin (RIF) and isoniazid (INH), cause a lasting disruption of gut flora, which is significantly associated with drug-induced toxicity...The key finding is that after antibiotics clear the gut microbiota, wolfberry failed to activate the YAP1/FXR pathway. Wolfberry comprehensively prevented liver damage under the condition of gut microbiota presence by enhancing gut microbiota diversity, strengthening intestinal barrier function, associating with the YAP1/FXR pathway."
Journal • Gastrointestinal Disorder • Hepatology • Infectious Disease • Liver Failure • Nephrology • Pulmonary Disease • Renal Disease • Respiratory Diseases • Tuberculosis • TJP1 • YAP1
December 11, 2025
Photodynamic Inactivation Enhances Antibiotic Efficacy Without Affecting Drug Stability: Insights into Photosensitizer-Antibiotic Combination Therapies.
(PubMed, Int J Mol Sci)
- "In this study, the tetracationic 5,10,15,20-tetra(4-N,N,N-trimethylammoniophenyl)porphyrin (TMAP4+) was evaluated in combination with ATBs: ampicillin (AMP) and rifampicin (RIF) against Staphylococcus aureus and cephalexin (CFX) against Escherichia coli. Growth curve analyses corroborated these results, showing delayed bacterial growth and decreased maximal optical densities in the combined treatments compared to single agents. Overall, these findings demonstrate that the photodynamic process can potentiate the antimicrobial effect of conventional ATBs without compromising their stability, supporting the potential of PS-ATB combination therapies as a valuable approach to improve antibacterial efficacy and mitigate ATB resistance."
Journal
December 11, 2025
Genomic landscape of Mycobacterium tuberculosis: Identifying mutation hotspots and stable regions for implications for drug development.
(PubMed, New Microbes New Infect)
- "These regions show mostly involved rrs mutations (amikacin, kanamycin, and capreomycin resistance), and rpoA has a compensatory role in rifampicin resistance. The most common nucleotide substitution was G to A (G→A) (16 %), followed by A to G (A→G) and T to C (T→C) (15 %). These findings collectively highlight novel genomic regions of stability and hypervariability, offering insights for refining WGS-based surveillance, resistance prediction, and future drug target prioritization."
Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis
December 11, 2025
GeneXpert MTB/RIF in diagnosis of tuberculous meningitis (TBM) in paediatric patients at a tertiary care children's hospital in Pakistan over a period of 4 years.
(PubMed, J Pak Med Assoc)
- "Rifampicin resistance was present in 3(2.9%) cases. The findings highlighted the importance of incorporating GeneXpert MTB/RIF testing in clinical evaluation for suspected tuberculous meningitis cases in paediatric patients."
Journal • Retrospective data • CNS Disorders • Infectious Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases • Tuberculosis
December 11, 2025
RIFA-SNAP: Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus
(clinicaltrials.gov)
- P3 | N=330 | Recruiting | Sponsor: Todd C. Lee MD MPH FIDSA | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular
December 11, 2025
QUANTUM: A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
(clinicaltrials.gov)
- P3 | N=532 | Recruiting | Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis
December 10, 2025
Genomic diversity and antimicrobial resistance of Vibrio cholerae isolates from Africa: a PulseNet Africa initiative using nanopore sequencing to enhance genomic surveillance.
(PubMed, Microb Genom)
- "AMR gene analysis revealed genes associated with resistance to trimethoprim in 96% of isolates and genes associated with resistance to quinolones in 83%, while genes associated with resistance to azithromycin, rifampicin and tetracycline remained low (≤7%). The widespread presence of genes associated with resistance to trimethoprim and quinolones raises concerns for treatment efficacy, although azithromycin and tetracycline remain viable options. WGS enables precise identification of species and genotyping, reinforcing PulseNet Africa's pivotal role in advancing genomic surveillance and enabling timely public health responses to cholera outbreaks."
Journal • Cholera • Infectious Disease
December 10, 2025
Evaluation of stool-based testing to diagnose tuberculosis in children using the Truenat platform in routine settings in Nigeria.
(PubMed, J Clin Microbiol)
- "The World Health Organization (WHO) recommends testing stool with Xpert MTB/RIF Ultra (Xpert-Ultra) as an initial diagnostic test for detection of tuberculosis (TB) and rifampicin resistance in children...Our study demonstrates that TB diagnostic testing for children can be provided in peripheral health facilities located in remote geographic areas with limited infrastructure where Truenat can be placed. Global scale-up will help further close the gap in childhood TB case finding."
Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis
December 10, 2025
Evaluation of the Simple One-Step (SOS) stool method for Truenat MTB plus and Xpert MTB/XDR assay.
(PubMed, J Clin Microbiol)
- "For rifampicin detection, 44.8% of results were indeterminate on Truenat, but none on GXU (except Trace calls)...Our findings further expand access to rapid molecular testing to detect TB and resistance to diverse anti-TB drugs for children and adults who cannot produce sputum. Increased access to TB testing in these vulnerable populations will support TB case finding efforts and timely and appropriate treatment."
Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis
December 10, 2025
Aortoesophageal fistula: Long-term survival with aggressive multidisciplinary management.
(PubMed, JTCVS Tech)
- "Definitive aortic surgery included aorta replacement with rifampin-soaked grafts in 8 (67%) and homografts in 4 (33%)...Management of AoEF is complex. However, aggressive multidisciplinary intervention with definitive esophageal and aortic repairs can result in good long-term survival in selected patients."
Journal • Cardiovascular • Gastrointestinal Disorder
December 10, 2025
Identification of Genetic and Environmental Factors Suppressing the Lethality and Antibiotic Susceptibility Mediated by Depletion of LptD, a Lipopolysaccharide Transport Protein.
(PubMed, J Microbiol Biotechnol)
- "Decreased expression of LptD strongly increased susceptibility to several antibiotics, such as clindamycin and rifampicin, and these increased susceptibilities were partially weakened by the deletion of aceE or ygfB. Collectively, these results can improve our understanding of the physiological functions and clinical importance of LptD."
Journal • Infectious Disease
December 09, 2025
Evaluation of in vitro toxicity of common phytochemicals included in weight loss supplements using 1H NMR spectroscopy.
(PubMed, FEBS Open Bio)
- "Of the phytochemicals evaluated, epigallocatechin-3,0-gallate (EGCG) was the only compound that caused a significant reduction in the viability of both cell lines (25.3% in HepG2 cells and 18.5% in Caco-2 cells), and this decrease was potentiated by CYP450 induction with rifampicin...While the remaining 11 active compounds analysed did not demonstrate significant toxicity in isolation, these require further assessment to determine their safety when used in combination with other phytochemicals. Given that the majority of WLS contain multiple herbal ingredients, each with a complex chemical composition, it is important to understand the role of interactions in adverse events."
Journal • Preclinical • Colon Cancer • Colorectal Cancer • Liver Cancer • Metabolic Disorders • Oncology • Solid Tumor • Targeted Protein Degradation
December 09, 2025
Clinical characteristics, antimicrobial susceptibility patterns, and treatment outcomes of nontuberculous mycobacterial diseases in eastern China: a retrospective cohort study (2019-2022).
(PubMed, Microbiol Spectr)
- "Antimicrobial susceptibility testing revealed that Mycobacterium avium complex exhibited relatively favorable sensitivity to clarithromycin, amikacin, ethambutol, rifapentine, rifampicin, and moxifloxacin, while the Mycobacterium chelonae/Mycobacterium abscessus complex showed sensitivity only to amikacin (66.7%). By linking pathogen types, drug resistance, and treatment duration to outcomes, this work equips doctors in Eastern China to diagnose faster, choose effective therapies, and improve patient survival. These findings also urge policymakers to prioritize localized data collection and standardized protocols for NTM management globally."
Journal • Retrospective data • Bronchiectasis • Chronic Cough • Cough • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis
1 to 25
Of
9886
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396